Client case · generic pharma · financial & market check
Launching a generic: entry economics vs the sales plan
An entry-economics check for a new generic on a national market — before the client invests in registration, the first batch, and promotion. The client, the active ingredient, and the market are under NDA; here we show the task, the method, and an honest negative result.
In brief
The client — a vertically integrated pharmaceutical holding company (retail, wholesale, and an online marketplace) — planned to bring a generic in the extended-release form of a well-known active ingredient to a national market, with a target volume of 50,000 packs per year. The entry-economics check produced a negative but unambiguous result: the planned volume coincides with the upper bound of all national demand for this ingredient, not with an achievable market share. Under a realistic forecast (median ≈ 14,000 packs per year by year five) the project does not reach the break-even point (≈ 18,200 packs as an importer) and is loss-making as a standalone legal entity. Economic sense survives only as a line in the holding company's overall portfolio — an asset worth roughly $8–27K, whereas the required promotion budget is $70–200K per year.
The starting situation
The client was considering launching a generic in the extended-release form of an active ingredient already present on the national market. The planned sales volume — 50,000 packs per year at the development horizon — was recorded in the client's handwritten note along with the dosage mix (60% low dose, 20% each for the medium and high doses). The product is not yet sold in the client's network, so the plan has no lower anchor in the form of actual sales: 50,000 is not an extrapolation of current sales but a target.
- The client's logic rested on the scale of its own infrastructure: according to one source, the holding company has access to roughly 4,000 of the country's pharmacies (split about evenly between private and state), including its own retail network of around 380 outlets.
- At first glance, 50,000 packs distribute across this network trivially — about 1 pack per pharmacy per month across the whole network, and 11 packs per month per own-retail outlet. The plan passes the "per-pharmacy" test easily — and that is exactly what created the sense of realism.
What the analysis showed
The "per-pharmacy" test measures the physical capacity of the distribution channel, not demand. As soon as the plan is set against the size of the market, the picture changes. On a Monte Carlo estimate (on data from a comparable market — there are no direct data for the national market), the entire market for the extended-release form of this ingredient lies in a range of 44,000 / 93,000 / 177,000 packs (P10/P50/P90). Against that, the planned 50,000 packs amount to about 54% of the median of the whole market for this form, and on the order of 30–50% of national consumption of the ingredient across all forms. The plan runs up not against a base-case growth scenario but against the physical ceiling of demand — to reach it, you would have to displace practically all competitors.
- Our own scenario model produced a range well below the plan: a realistic median by year five of around 14,000 packs per year, and a base case of around 5,300 — roughly ten times below the client's plan. The margin proved fragile: the stated 22% is achievable only if the holding company itself acts as the importer; in a pure-wholesaler role it falls to ~13%, and the break-even point shifts from ≈ 18,200 to ≈ 30,800 packs per year.
- Positive net profit in the table below comes only from the planned 50,000-pack scenario — the one that coincides with the upper bound of demand and has a probability of below 1%. All realistic scenarios (up to ≈ 18,000 packs) lie below the break-even point and, at the year-five horizon, are loss-making as a standalone legal entity: the fixed costs of a separate company (≈ $18K per year) are not recovered. The asset valuation in the table uses a multiple, under the "holding-as-importer" role with a 22% margin.
- On top of that comes price pressure: the market already has three registered brands of the extended-release form, including a recently launched cheap imported generic. Pricing 20% below the leader may prove insufficient — if the cheapest competitor is priced even lower, the price core of the whole model collapses. The competitor's retail price was not obtained in the project — this is a deliberate data gap, not an assumption.
| Scenario | Volume, year 5 (packs/year) | Net profit, year 5 | Asset valuation |
|---|---|---|---|
| Conservative | ≈ 1,530 | −$16.7K | $2.3K |
| Base case | ≈ 5,300 | −$13.3K | $7.3K |
| Optimistic | ≈ 17,900 | −$2.8K | $23.1K |
| Client's plan | 50,000 | +$23.7K | $62.9K |
| Break-even point | ≈ 18,200 | 0 | — |
The bottom line
As a standalone business the entry is loss-making: realistic demand (median ≈ 14,000 packs) falls short of the break-even point (≈ 18,200 packs as an importer). Economic sense survives only as a single line in the holding company's overall portfolio, where costs are spread across the whole range. The value of such an asset at the working point is on the order of $8–27K. Meanwhile, the promotion budget for a prescription drug is estimated at $70–200K per year — that is, the promotion spend exceeds the value of the asset it creates many times over.
The result
The client received not an "attractiveness assessment" but a map of the project's economic boundaries, with numbers. In practice this let them avoid entering the project under mistaken volume expectations and avoid funding promotion that would not pay off: the launch decision moved from the question of "how much will we sell" to "on what supply-chain and portfolio terms does this make sense at all." Three conclusions had direct operational significance:
- The 50,000-pack planning figure was reclassified from a "sales target" into a "demand ceiling" — that is, a limit rather than a plan. This shifted expectations toward a realistic range of 5–18K packs.
- The profitability condition became explicit: the project makes sense only if the holding company imports the product itself (22% margin) and treats it as a portfolio line rather than a standalone business. The role in the import chain turned out to be a critical economic parameter, not a detail.
- An internal contradiction was exposed: spending $70–200K per year to promote an asset worth $8–27K is economically untenable. This stopped the preparation of a costly promotion campaign before it launched.
Why this is value, not criticism
A negative result on entry economics is not a verdict on the idea but the removal of expensive uncertainty at the cheapest stage.
- An error in the planned volume (50,000 instead of a realistic 14,000) is exposed by a calculation in a matter of weeks. The same error discovered after registration, purchase of the first batch, and the launch of promotion would cost many times more — in money and in working capital frozen in unsold packs.
- The check separated the physical capacity of the distribution channel (which the plan passed easily) from real demand (against which the plan was a ceiling). The client kept the option to enter the market deliberately — as a portfolio line under its own import — instead of building a separate loss-making business around it. An honest negative result at the entry is worth more than an optimistic forecast that falls apart on the first batch.
Caveats and data status
We separate what is confirmed by a primary source, what is a calculated estimate, and what is taken from the client's own account.
- Registry data (confirmed): the presence of three registered brands of the extended-release form and their registration parameters were obtained by a direct query to the state medicines registry — these are registry data, not search-result headlines.
- Model estimates: the market size (P10/P50/P90 = 44,000 / 93,000 / 177,000 packs) was computed by a Monte Carlo method on data from a comparable market — there are no direct data for the national market. The scenario volumes, the break-even point (≈ 18,200 / ≈ 30,800 packs), the asset valuation ($8–27K), and the registration timelines are calculated estimates on accepted assumptions for price, margin, and dose mix.
- From the client's account: the planned volume of 50,000 packs and the dosage mix (60/20/20) are taken from the client's note as is; the product is not yet sold in the network, so there are no actual sales to calibrate the forecast. The promotion budget ($70–200K per year) and the fixed costs are expert order-of-magnitude estimates.
- Known gaps: the retail price of the cheapest competitor was not obtained; the client's willingness to fund entry through the state and private channels is an open question for the client. These gaps are flagged explicitly in the report and are not papered over with assumptions.
Need this kind of entry-economics check?
Message us — we'll show the method and scope a financial and market check for your product and market.
This material is informational and is not medical advice, a regulatory opinion, or investment advice. The numerical results come from the project's financial model (a scenario-based profit-and-loss calculation, an import-cost calculation by dose, a risk register, a fixed project fact sheet, revision v3) with explicitly flagged assumptions and data gaps; applying them to a specific product requires a separate check. The client, the active ingredient, the trade marks, the national market, and the city are under NDA.